CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Summary

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.

Conditions

• HER2-positive
• Adenocarcinoma
• Bile Duct Cancer
• Biliary Tract Cancer
• Bladder Cancer
• Breast Cancer
• Breast Neoplasm
• Carcinoma, Ductal
• Carcinoma, Hepatocellular
• Cancer
• Lung Cancer, Non-Small-Cell
• Carcinoma, Ovarian Epithelial
• Carcinoma, Small Cell
• Carcinoma, Squamous
• Carcinoma, Transitional Cell
• Colorectal Cancer
• Esophagogastric Junction Neoplasms
• Inflammatory Breast Cancer
• Stomach Neoplasms
• Malignant Neoplasms
• Ovarian Neoplasms
• Pancreatic Cancer
• HER2-positive Solid Tumors
• HER2-positive Breast Cancer
• HER2-positive Gastric Cancer
• HER-2 Protein Overexpression
• HER-2 Gene Amplification
• Prostate Cancer
• Head and Neck Cancer
• Endometrial Cancer
• Lung Cancer, Small Cell

Interventions

BIOLOGICAL

CT-0508

anti-HER2 CAR macrophages

BIOLOGICAL

Pembrolizumab

anti-PD antibody

Sponsors & Collaborators

• Carisma Therapeutics Inc

  lead INDUSTRY

Principal Investigators

• Jeanett Wetzel · Carisma Therapeutics

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-02-02

Primary Completion

2024-12-31

Completion

2024-12-31

FDA Drug

Yes

Countries

• United States

Study Locations